Table 2.
Molecular testing results for stage IV NSCLC non-squamous patients by region
| Molecular testing results | Region |
Total | |||
|---|---|---|---|---|---|
| Lampang | Penang | Singapore | Yogyakarta | ||
| Cases (N) | 374 | 184 | 647 | 323 | 1528 |
| EGFR molecular mutation testing carried out, n (%) | 52 (13.9) | 109 (59.2) | 626 (96.8) | 237 (73.4) | 1024 (67.0) |
| Positive | 24 (46.2) | 61 (56.0) | 367 (58.6) | 142 (59.9) | 594 (58.0) |
| Deletion exon 19 | 15 (28.8) | 37 (33.9) | 178 (28.4) | 73 (30.8) | 303 (29.6) |
| Point mutation exon 21 | 6 (11.5) | 21 (19.3) | 148 (23.6) | 31 (13.1) | 206 (20.1) |
| Other | 3 (5.8) | 3 (2.8) | 41 (6.5) | 38 (16.0) | 85 (8.3) |
| ALK gene rearrangement testing carried out, n (%) | 23 (6.1) | 46 (25.0) | 577 (89.2) | 1 (0.3) | 647 (42.3) |
| Positive | 5 (21.7) | 5 (10.9) | 40 (6.9) | 1 (100.0) | 51 (7.9) |
| ROS1 gene rearrangement testing carried out, n (%) | 7 (1.9) | 21 (11.4) | 570 (88.1) | 0 (0.0) | 598 (39.1) |
| Positive | 2 (28.6) | 0 (0) | 11 (1.9) | 0 (0) | 13 (2.2) |
| BRAF V600 mutation testing carried out, n (%) | 1 (0.3) | 5 (2.7) | 113 (17.5) | 0 (0.0) | 119 (7.8) |
| Positive | 0 (0) | 0 (0) | 1 (0.9) | 0 (0) | 1 (0.8) |
| PD-L1 immunohistochemistry testing carried out, n (%) | 14 (3.7) | 42 (22.8) | 494 (76.4) | 2 (0.6) | 552 (36.1) |
| Positivea | 6 (42.9) | 25 (59.5) | 344 (69.6) | 1 (50.0) | 376 (68.1) |
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer; PD-L1, programmed death-ligand 1.
a
PD-L1-positive immunohistochemistry ≥1% tumor cells.